0      0

LV09 - Improving Outcomes for Women with Metastatic HER2-Positive Breast Cancer

‐ Nov 11, 2023 12:15pm

Learning Objectives:

  • Discuss recent FDA approvals and practice guideline updates related to advancing care for patients with metastatic HER2-overexpressing breast cancer.
  • Interpret the increased clinical relevance of the new "HER2-low" category of HER2 expression for the treatment of patients with metastatic breast cancer.
  • Apply evidence-based best practices when monitoring and managing adverse events associated with novel HER2-targeted agents when caring for patients with metastatic breast cancer.


You must be logged in and own this session in order to post comments.